PMID: 6407958Mar 1, 1983Paper

Fibronectin and factor VIII-related antigen in acute leukaemia

Hoppe-Seyler's Zeitschrift für physiologische Chemie
H G KlingemannK Havemann

Abstract

The glycoprotein fibronectin is, as well as by various other cells, also produced in leucocytes and is said to play an important role in malignant transformation of cells. Therefore, the behaviour of plasma fibronectin and of factor VIII R:AG was investigated in acute leukaemia in order to prove their significance as prognostic and therapeutic markers (method: electroimmunoassay). In patients with acute myeloid leukaemia (n = 29) and acute lymphoblastic leukaemia (n = 11) no significant changes in fibronectin concentration could be evaluated. Fibronectin levels declined significantly only during therapy with asparaginase in patients with acute lymphoblastic leukaemia, probably as a result of disturbed synthesis in the liver. Using crossed immunoelectrophoresis against fibronectin antiserum, one normal and one slower migrating antigen (FN:C) could be observed in nearly all plasma samples in patients with acute leukaemia. By means of in vitro tests with highly purified substances and intermediate gel electrophoresis it could be shown that FN:C represents fibronectin which has bound fibrinogen, probably crosslinked by activated factor XIII. Factor VIII R:AG was found to be greatly raised in patients with acute leukaemia--up to 140...Continue Reading

References

Sep 1, 1974·Hoppe-Seyler's Zeitschrift für physiologische Chemie·W Schmidt, K Havemann
Oct 15, 1982·Klinische Wochenschrift·H Hörmann
Mar 1, 1980·The Journal of Experimental Medicine·K AlitaloA Vaheri

❮ Previous
Next ❯

Citations

Jan 1, 1985·Rheumatology International·D L ScottK W Walton
Apr 30, 1985·Clinica Chimica Acta; International Journal of Clinical Chemistry·M CucuianuS Roman
Dec 1, 1983·Journal of Clinical Pathology·J T ReillyM J Mackie
Jan 1, 1986·Critical Reviews in Clinical Laboratory Sciences·E L Snyder, N L Luban
Oct 1, 1984·The American Journal of Medicine·G Zerlauth, G Wolf
Mar 15, 1985·Thrombosis Research·J MarrinkE G de Vries
Feb 1, 1984·Thrombosis Research·J T ReillyB A McVerry
Sep 1, 1984·British Journal of Haematology·J T ReillyB A McVerry
Nov 1, 1986·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·P L AlmasioR Williams
May 1, 1985·British Journal of Haematology·G NalliG Casirola
Jul 1, 1985·British Journal of Haematology·E VellengaE G de Vries
Nov 17, 1988·Biochimica Et Biophysica Acta·R Procyk, B Blomback

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.